At a glance
- Originator Sanofi-Synthelabo
- Class Antihypertensives; Peptides
- Mechanism of Action Neuropeptide Y receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 11 Aug 1998 No-Development-Reported for Cardiovascular disorders in France (PO)
- 11 Aug 1998 No-Development-Reported for Cardiovascular disorders in USA (PO)
- 30 Aug 1996 Preclinical development for Cardiovascular disorders in France (PO)